Zobrazeno 1 - 10
of 25
pro vyhledávání: '"MOSTAFA ELHILALI"'
Publikováno v:
The Canadian journal of urology. 23(5)
Patients with pelvic kidneys are at an increased risk of developing ureteropelvic junction obstruction (UPJO) and nephrolithiasis with limited endourologic options. A 54-year-old man with a left pelvic kidney, recurrent nephrolithiasis, and 12 previo
Publikováno v:
BJU International. 97:1242-1246
OBJECTIVE To determine the efficacy and safety of the selective α1-blocker alfuzosin in men with lower urinary tract symptoms (LUTS) and painful ejaculation, compared with those with LUTS only, as painful ejaculation is one of the most prevalent, di
Autor:
ERNEST W. RAMSEY, MOSTAFA ELHILALI, S. LARRY GOLDENBERG, CURTIS J. NICKEL, RICHARD NORMAN, JEAN PAUL PERREAULT, BRUCE PIERCY, JOHN TRACHTENBERG FOR THE CANADIAN PROSTATE HEALTH COUNCIL
Publikováno v:
Journal of Urology. 163:499-502
Purpose: We reviewed the practice patterns of Canadian urologists in benign prostatic hyperplasia (BPH) and prostate cancer, and assessed the changes that occurred between 1995 and 1998.Materials and Methods: In 1995 and 1998 questionnaires were mail
Autor:
Martin E. Gleave, Mostafa Elhilali, Yves Fradet, Ian Davis, Peter Venner, Fred Saad, Laurence H. Klotz, Malcolm J. Moore, Virginia Paton, Alex Bajamonde, David Bell, Scott Ernst, Ernest Ramsey, Joe Chin, Alvaro Morales, Heidi Martins, Coree Sanders
Publikováno v:
New England Journal of Medicine. 338:1265-1271
Background Most trials of immunomodulators in metastatic renal-cell carcinoma have been uncontrolled and subject to selection bias. The objective of this blinded, placebo-controlled study was to compare overall response rates, time to disease progres
Autor:
Mostafa Elhilali, Gianpaolo Capolicchio, Yves L. Homsy, A.M. Houle, Lawrence Stein, Alex Brzezinski
Publikováno v:
Journal of Urology. 158:1534-1537
Purpose: We reviewed our experience with the safety and long-term efficacy of percutaneous endopyelotomy in children with secondary ureteropelvic junction obstruction who previously underwent open pyeloplasty.Materials and Methods: Nine patients a me
Autor:
Zineb Bahlaouan, Mohamed Abarbri, Mostafa Elhilali, Alain Duchêne, Jérôme Thibonnet, Jean-Luc Parrain
Publikováno v:
ChemInform. 43
A simple method is presented for the preparation of pharmaceutically important title compounds (III).
Autor:
Alain Duchêne, Mostafa Elhilali, Mohamed Abarbri, Zineb Bahlaouan, Jérôme Thibonnet, Jean-Luc Parrain
Publikováno v:
SYNLETT
SYNLETT, 2011, 17, pp.2509-2512. ⟨10.1055/s-0030-1260323⟩
SYNLETT, Georg Thieme Verlag, 2011, pp.2509-2512. ⟨10.1055/s-0030-1260323⟩
SYNLETT, 2011, 17, pp.2509-2512. ⟨10.1055/s-0030-1260323⟩
SYNLETT, Georg Thieme Verlag, 2011, pp.2509-2512. ⟨10.1055/s-0030-1260323⟩
International audience; A general and efficient method of copper-catalyzed amination of 2-iodobenzenesulfonamide has been developed under very mild conditions, with good to excellent yields. This method uses inexpensive copper(I) iodide as catalyst,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eb137c6f6054ae68ac80dc8194e8701
https://hal.inrae.fr/hal-02645591
https://hal.inrae.fr/hal-02645591
Autor:
Mostafa Elhilali
Publikováno v:
Journal of Urology. 193:1376-1376
Autor:
Fred, Saad, J Curtis, Nickel, Luc, Valiquette, Richard, Casey, Irwin, Kuzmarov, Mostafa, Elhilali
Publikováno v:
The Canadian journal of urology. 12(4)
A novel slow release formulation of alfuzosin should improve compliance by reducing dosing to one 10 mg tablet per day. The current study examined efficacy, at 9 days and 3 months, and safety of this formulation of alfuzosin in BPH patients.ALF-X was
Autor:
J Curtis, Nickel, Sender, Herschorn, Jacques, Corcos, Bryan, Donnelly, Doug, Drover, Mostafa, Elhilali, Larry, Goldenberg, John, Grantmyre, Bruno, Laroche, Richard, Norman, Bruce, Piercy, Karen, Psooy, Gary, Steinhoff, John, Trachtenberg, Fred, Saad, Simon, Tanguay
Publikováno v:
The Canadian journal of urology. 12(3)
To develop the first Canadian guidelines for the management of lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH).These guidelines, developed under a mandate provided by the Canadian Urological Association (CUA), were a colla